The Pathophysiology of Long-term Neuromuscular and Cognitive Outcomes Following Critical Illness

Critical Care Clinics

Volumn 24, Issue 1, 2008, Pages 179-199

  Herridge, Margaret S ^a   Batt, Jane ^b   Hopkins, Ramona O ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c LDS HOSPITAL   (United States)

^d BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANALGESIC AGENT; APOLIPOPROTEIN E4; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FUROSEMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPERTENSIVE FACTOR; INTERLEUKIN 1; NEUROMUSCULAR BLOCKING AGENT; OPIATE; SALMONELLA ENDOTOXIN; SEDATIVE AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA;

AGING; ARTIFICIAL VENTILATION; ASTHMATIC STATE; BRAIN INJURY; CHRONIC DISEASE; COGNITIVE DEFECT; CRITICAL ILLNESS; DELIRIUM; DEMENTIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOXEMIA; INTENSIVE CARE; LONG TERM CARE; MORBIDITY; MORTALITY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE INJURY; MUSCLE WEAKNESS; MYOPATHY; NEUROMUSCULAR DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POLYNEUROPATHY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; COGNITION DISORDERS; HUMANS; NEUROMUSCULAR DISEASES; POLYNEUROPATHIES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 38749122140     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2007.11.002     Document Type: Review

References (161)

1. Schmitz R., Lantin M., and White A. Future workforce needs in pulmonary and critical care medicine (1998), Abt. Associates, Cambridge (MA)
2. Esteban A., Anzueto A., Alia I., et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med 161 (2000) 1450-1458
3. Angus D.C., and Carlet J. Surviving intensive care: a report from the 2002 Brussels Roundtable. Intensive Care Med 29 (2003) 368-377
4. Herridge M.S., Cheung A.M., Tansey C.M., et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 348 (2003) 683-693
5. Hopkins R.O., Weaver L.K., Collingridge D., et al. Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med 171 (2005) 340-347
6. Cheung A.M., Tansey C.M., Tomlinson G., et al. Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 174 (2006) 538-544
7. Dowdy D.W., Eid M.P., Dennison C.R., et al. Quality of life after acute respiratory distress syndrome: a meta-analysis. Intensive Care Med 32 (2006) 1115-1124
8. Vincent J.L., Moreno R., Takala J., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22 (1996) 707-710
9. Griffiths R.D., and Jones C. Recovery from intensive care. BMJ 319 (1999) 427-429
10. Angus D.C., Musthafa A.A., Clermont G., et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 163 (2001) 1389-1394
11. Herridge M.S., Tansey C.M., Matte A., et al. Five-year pulmonary, functional, and QOL outcomes in ARDS survivors. Am J Respir Crit Care Med Suppl (2006) A831
12. Hopkins R.O., Weaver L.K., Pope D., et al. Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Am J Respir Crit Care Med 160 (1999) 50-56
13. Bolton C.F., Gilbert J.J., Hahn A.F., et al. Polyneuropathy in critically ill patients 1. J Neurol Neurosurg Psychiatry 47 (1984) 1223-1231
14. Pandit L., and Agrawal A. Neuromuscular disorders in critical illness. Clin Neurol Neurosurg 108 (2006) 621-627
15. de Letter M.A., Schmitz P.I., Visser L.H., et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients 2. Crit Care Med 29 (2001) 2281-2286
16. De Jonghe B., Sharshar T., Lefaucheur J.P., et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 288 (2002) 2859-2867
17. Stevens R.D., Dowdy D.W., Michaels R.K., et al. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med 33 (2007) 1876-1891
18. Van den B.G., Schoonheydt K., Becx P., et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 64 (2005) 1348-1353
19. Fenzi F., Latronico N., Refatti N., et al. Enhanced expression of E-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. Acta Neuropathol (Berl) 106 (2003) 75-82
20. Hotchkiss R.S., Swanson P.E., Freeman B.D., et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27 (1999) 1230-1251
21. Van den B.G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 (2001) 1359-1367
22. Van den B.G., Wilmer A., Hermans G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 (2006) 449-461
23. Vanhorebeek I., De V.R., Mesotten D., et al. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients 1. Lancet 365 (2005) 53-59
24. Deem S., Lee C.M., and Curtis J.R. Acquired neuromuscular disorders in the intensive care unit 1. Am J Respir Crit Care Med 168 (2003) 735-739
25. Siroen M.P., van Leeuwen P.A., Nijveldt R.J., et al. Modulation of asymmetric dimethyl arginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? 1. Crit Care Med 33 (2005) 504-510
26. Aljada A., Ghanim H., Mohanty P., et al. Insulin inhibits the proinflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations 1. J Clin Endocrinol Metab 87 (2002) 1419-1422
27. Ishii D.N., and Lupien S.B. Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats. J Neurosci Res 40 (1995) 138-144
28. Garnacho-Montero J., Madrazo-Osuna J., Garcia-Garmendia J.L., et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients 1. Intensive Care Med 27 (2001) 1288-1296
29. Leatherman J.W., Fluegel W.L., David W.S., et al. Muscle weakness in mechanically ventilated patients with severe asthma 1. Am J Respir Crit Care Med 153 (1996) 1686-1690
30. Behbehani N.A., Al-Mane F., D'yachkova Y., et al. Myopathy following mechanical ventilation for acute severe asthma: the role of muscle relaxants and corticosteroids 1. Chest 115 (1999) 1627-1631
31. MacFarlane I.A., and Rosenthal F.D. Severe myopathy after status asthmaticus 2. Lancet 2 (1977) 615
32. Thiele R.I., Jakob H., Hund E., et al. Sepsis and catecholamine support are the major risk factors for critical illness polyneuropathy after open heart surgery. Thorac Cardiovasc Surg 48 (2000) 145-150
33. Latronico N., Fenzi F., Recupero D., et al. Critical illness myopathy and neuropathy. Lancet 347 (1996) 1579-1582
34. Campellone J.V., Lacomis D., Kramer D.J., et al. Acute myopathy after liver transplantation. Neurology 50 (1998) 46-53
35. Helliwell T.R., Coakley J.H., Wagenmakers A.J., et al. Necrotizing myopathy in critically-ill patients. J Pathol 164 (1991) 307-314
36. Lacomis D. Critical illness myopathy. Curr Rheumatol Rep 4 (2002) 403-408
37. Winkelman C. Inactivity and inflammation: selected cytokines as biologic mediators in muscle dysfunction during critical illness 1. AACN Clin Issues 15 (2004) 74-82
38. Allen D.C., Arunachalam R., and Mills K.R. Critical illness myopathy: further evidence from muscle fiber excitability studies of an acquired channelopathy 1. Muscle Nerve 37 (2007) 14-22
39. Dutta C., and Hadley E.C. The significance of sarcopenia in old age. J Gerontol A Biol Sci Med Sci 50 (1995) 1-4
40. Janssen I., Shepard D.S., Katzmarzyk P.T., et al. The health care costs of sarcopenia in the United States. J Am Geriatr Soc 52 (2004) 80-85
41. Visser M., Pahor M., Taaffe D.R., et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study 1. J Gerontol A Biol Sci Med Sci 57 (2002) M326-M332
42. Giresi P.G., Stevenson E.J., Theilhaber J., et al. Identification of a molecular signature of sarcopenia. Physiol Genomics 21 (2005) 253-263
43. Roth S.M., Metter E.J., Ling S., et al. Inflammatory factors in age-related muscle wasting 2. Curr Opin Rheumatol 18 (2006) 625-630
44. Petersen A.M., and Pedersen B.K. The anti-inflammatory effect of exercise. J Appl Physiol 98 (2005) 1154-1162
45. Morris P.E. Moving our critically ill patients: mobility barriers and benefits. Crit Care Clin 23 (2007) 1-20
46. Medina R., Wing S.S., and Goldberg A.L. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J 307 Pt 3 (1995) 631-637
47. Price S.R., Bailey J.L., Wang X., et al. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest 98 (1996) 1703-1708
48. Temparis S., Asensi M., Taillandier D., et al. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res 54 (1994) 5568-5573
49. Voisin L., Breuille D., Combaret L., et al. Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+ -activated, and ubiquitin-proteasome proteolytic pathways. J Clin Invest 97 (1996) 1610-1617
50. Taillandier D., Aurousseau E., Meynial-Denis D., et al. Coordinate activation of lysosomal, Ca 2+-activated and ATP-ubiquitin-dependent proteinases in the unweighted rat soleus muscle. Biochem J 316 Pt 1 (1996) 65-72
51. Bodine S.C., Latres E., Baumhueter S., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 (2001) 1704-1708
52. Gomes M.D., Lecker S.H., Jagoe R.T., et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 98 (2001) 14440-14445
53. Stitt T.N., Drujan D., Clarke B.A., et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14 (2004) 395-403
54. Stevenson E.J., Giresi P.G., Koncarevic A., et al. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J Physiol 551 (2003) 33-48
55. Lecker S.H., Jagoe R.T., Gilbert A., et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18 (2004) 39-51
56. Centner T., Yano J., Kimura E., et al. Identification of muscle-specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 306 (2001) 717-726
57. Sandri M., Sandri C., Gilbert A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117 (2004) 399-412
58. Koohmaraie M. Ovine skeletal muscle multicatalytic proteinase complex (proteasome): purification, characterization, and comparison of its effects on myofibrils with mu-calpains. J Anim Sci 70 (1992) 3697-3708
59. Huang J., and Forsberg N.E. Role of calpain in skeletal muscle protein degradation. Proc Natl Acad Sci U S A 95 (1998) 12100-12105
60. Hasselgren P.O., Wray C., and Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 290 (2002) 1-10
61. Spate U., and Schulze P.C. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 7 (2004) 265-269
62. Cai D., Frantz J.D., Tawa Jr. N.E., et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119 (2004) 285-298
63. Sandri M. Apoptotic signaling in skeletal muscle fibers during atrophy. Curr Opin Clin Nutr Metab Care 5 (2002) 249-253
64. Du J., Wang X., Miereles C., et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113 (2004) 115-123
65. Lee S.W., Dai G., Hu Z., et al. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 15 (2004) 1537-1545
66. Jackson J.C., Hart R.P., Gordon S.M., et al. Six-month neuropsychological outcome of medical intensive care unit patients. Crit Care Med 31 (2003) 1226-1234
67. Jones C., Griffiths R.D., Slater T., et al. Significant cognitive dysfunction in nondelirious patients identified during and persisting following critical illness. Intensive Care Med 32 (2006) 923-926
68. Suchyta M.R., and Hopkins R.O. The incidence of cognitive dysfunction after ARDS. Am J Respir Crit Care Med 169 7 (2004) A18 [Ref Type: Abstract]
69. Sukantarat K.T., Burgess P.W., Williamson R.C., et al. Prolonged cognitive dysfunction in survivors of critical illness. Anaesthesia 60 (2005) 847-853
70. Marquis K.S., Curtis J.R., Caldwell E.S., et al. Neuropsychological sequelae in survivors of ARDs compared to critically ill control patients. Am J Respir Crit Care Med 161 (2007) A383 [Ref Type: Abstract]
71. Al Saidi F., McAndrews M.P., Cheung A.M., et al. Neuropsychological sequelae in ARDS survivors. Am J Respir Crit Care Med 167 7 (2003) A737 [Ref Type: Abstract]
72. Jackson J.C., Gordon S.M., Burger C., et al. Acute respiratory distress syndrome and long-term cognitive impairment: a case study. Arch Clin Neuropsychol 18 7 (2003) 688 [Ref Type: Abstract]
73. Rothenhausler H.B., Ehrentraut S., Stoll C., et al. The relationship between cognitive performance and employment and health status in long-term survivors of the acute respiratory distress syndrome: results of an exploratory study. Gen Hosp Psychiatry 23 (2001) 90-96
74. Christie J.D., DeMissie E., Gaughan C., et al. Validity of a brief telephone-administered battery to assess cognitive function in survivors of adult respiratory distress syndrome (ARDS). Am J Respir Crit Care Med 169 7 (2004) A781 [Ref Type: Abstract]
75. Hopkins R.O., Weaver L.K., Chan K.J., et al. Quality of life, emotional, and cognitive function following acute respiratory distress syndrome. J Int Neuropsychol Soc 10 (2004) 1005-1017
76. Hopkins RO, Jackson JC, Wallace CJ. Neurocogintive inpairments in ICU patients with prolonged mechanical ventilation. International Neuropsychological Society 33rd Annual Meeting Program and Abstracts. St. Louis, MO, 2005 [Ref Type: Abstract].
77. Starr J.M., and Whalley L.J. Drug-induced dementia. Incidence, management, and prevention. Drug Saf 11 (1994) 310-317
78. Jackson J.C., Gordon S.M., Hart R.P., et al. The association between delirium and cognitive decline: a review of the empirical literature. Neuropsychol Rev 14 (2004) 87-98
79. Elenkov I.J., Iezzoni D.G., Daly A., et al. Cytokine dysregulation, inflammation, and well-being. Neuroimmunomodulation 12 (2005) 255-269
80. Fries M., Bickenbach J., Henzler D., et al. S-100 protein and neurohistopathologic changes in a porcine model of acute lung injury. Anesthesiology 102 (2005) 761-767
81. Hopkins R.O., Myers C.E., Shohamy D., et al. Impaired probabilistic category learning in hypoxic subjects with hippocampal damage. Neuropsychologia 42 (2004) 524-535
82. Gale S.D., and Hopkins R.O. Effects of hypoxia on the brain: neuroimaging and neuropsychological findings following carbon monoxide poisoning and obstructive sleep apnea. J Int Neuropsychol Soc 10 (2004) 60-71
83. Hopkins R.O., Gale S.D., Johnson S.C., et al. Severe anoxia with and without concomitant brain atrophy and neuropsychological impairments. J Int Neuropsychol Soc 1 (1995) 501-509
84. Graham D.I., Gennarelli T.A., and McIntosh T.K. Trauma. In: Graham D.I., and Lantos P.I. (Eds). Greenfield's neuropatholoty. 7th edition (2002), Edward Arnodl, Hoder Headline Group, London 823-882
85. Grant I., Heaton R.K., McSweeny A.J., et al. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 142 (1982) 1470-1476
86. Heaton R.K., Grant I., McSweeny A.J., et al. Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 143 (1983) 1941-1947
87. Manns J.R., Hopkins R.O., and Squire L.R. Semantic memory and the human hippocampus. Neuron 38 (2003) 127-133
88. Bayley P.J., Hopkins R.O., and Squire L.R. Successful recollection of remote autobiographical memories by amnesic patients with medial temporal lobe lesions. Neuron 38 (2003) 135-144
89. Browne S.M., Halligan P.W., Wade D.T., et al. Postoperative hypoxia is a contributory factor to cognitive impairment after cardiac surgery. J Thorac Cardiovasc Surg 126 (2003) 1061-1064
90. Johnston M.V., Nakajima W., and Hagberg H. Mechanisms of hypoxic neurodegeneration in the developing brain. Neuroscientist 8 (2002) 212-220
91. Lutz P.L., and Nilsson G.E. The brain without oxygen: causes of failure and mechanisms for survival (1994), R.G. Landes Company, Austin (TX)
92. Michenfelder J.D., and Sundt Jr. T.M. Cerebral ATP and lactate levels in the squirrel monkey following occlusion of the middle cerebral artery. Stroke 2 (1971) 319-326
93. Siesjo B.K. Cell damage in the brain: a speculative synthesis. J Cereb Blood Flow Metab 1 (1981) 155-185
94. Olney J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164 (1969) 719-721
95. Siesjo B.K., Bengtsson F., Grampp W., et al. Calcium, excitotoxins, and neuronal death in the brain. Ann N Y Acad Sci 568 (1989) 234-251
96. Kass I.S., and Lipton P. Calcium and long-term transmission damage following anoxia in dentate gyrus and CA1 regions of the rat hippocampal slice. J Physiol 378 (1986) 313-334
97. Schurr A., Lipton P., West C.A., et al. The role of energy in metabolism and divalent cations in the neurotoxity of excitatory amino acids in vitro. Pharmacology of cerebral ischaemia (1990), CRC Press, Boca Raton (FL) p. 217-26
98. Biagas K. Hypoxic-ischemic brain injury: advancements in the understanding of mechanisms and potential avenues for therapy. Curr Opin Pediatr 11 (1999) 223-228
99. Granger D.N., McCord J.M., Parks D.A., et al. Xanthine oxidase inhibitors attenuate ischemia-induced vascular permeability changes in the cat intestine. Gastroenterology 90 (1986) 80-84
100. Floyd R.A. Role of oxygen-free radicals in carcinogenesis and brain ischemia. FASEB J 4 (1990) 2587-2597
101. Steller H. Mechanisms and genes of cellular suicide. Science 267 (1995) 1445-1449
102. Oniki T.A., and Gardner R.M. Computerized detection of arterial oxygen desaturations in an intensive care unit. Proc Annu Symp Comput Appl Med Care (1993) 356-360
103. Trzepacz P.T. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 5 (2000) 132-148
104. Meagher D.J., and Trzepacz P.T. Motoric subtypes of delirium. Semin Clin Neuropsychiatry 5 (2000) 75-85
105. Arvin B., Neville L.F., Barone F.C., et al. Brain injury and inflammation. A putative role of TNF alpha. Ann N Y Acad Sci 765 (1995) 62-71 [discusion: 98-9]
106. * 6: the pathogenesis of ALI/ARDS. Thorax 57 (2002) 540-546
107. Francis J., Martin D., and Kapoor W.N. A prospective study of delirium in hospitalized elderly. JAMA 263 (1990) 1097-1101
108. De Kloet E.R., Vreugdenhil E., Oitzl M.S., et al. Brain corticosteroid receptor balance in health and disease. Endocr Rev 19 (1998) 269-301
109. Capes S.E., Hunt D., Malmberg K., et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32 (2001) 2426-2432
110. Gardiner M., Smith M.L., Kagstrom E., et al. Influence of blood glucose concentration on brain lactate accumulation during severe hypoxia and subsequent recovery of brain energy metabolism. J Cereb Blood Flow Metab 2 (1982) 429-438
111. Young B., Ott L., Dempsey R., et al. Relationship between admission hyperglycemia and neurologic outcome of severely brain-injured patients. Ann Surg 210 (1989) 466-472 [discussion: 72-3]
112. Pulsinelli W.A., Levy D.E., Sigsbee B., et al. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med 74 (1983) 540-544
113. Ryan C.M., Williams T.M., Finegold D.N., et al. Cognitive dysfunction in adults with type 1 (insulin-dependent) diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 36 (1993) 329-334
114. Bauer P.J., and Hertsgaard L.A. Increasing steps in recall of events: factors facilitating immediate and long-term memory in 13.5- and 16.5-month-old children. Child Dev 64 (1993) 1204-1223
115. Wieloch T. Hypoglycemia-induced neuronal damage prevented by an N-methyl-D-aspartate antagonist. Science 230 (1985) 681-683
116. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271 (1996) C1424-C1437
117. Hopkins RO, Suchyta MR, Jephson A, et al. Hyperglycemia and neurocognitive outcomes in ARDS survivors. Pro Am Thorac Soc 2 [Abstracts], A36. 2005 [Ref Type: Abstract].
118. Levine S.R., Welch K.M., Helpern J.A., et al. Prolonged deterioration of ischemic brain energy metabolism and acidosis associated with hyperglycemia: human cerebral infarction studied by serial 31P NMR spectroscopy. Ann Neurol 23 (1988) 416-418
119. Rehncrona S., Rosen I., and Siesjo B.K. Excessive cellular acidosis: an important mechanism of neuronal damage in the brain?. Acta Physiol Scand 110 (1980) 435-437
120. Welsh F.A., Ginsberg M.D., Rieder W., et al. Deleterious effect of glucose pretreatment on recovery from diffuse cerebral ischemia in the cat. II. Regional metabolite levels. Stroke 11 (1980) 355-363
121. Clifton G.L., Ziegler M.G., and Grossman R.G. Circulating catecholamines and sympathetic activity after head injury. Neurosurgery 8 (1981) 10-14
122. Haider W., Benzer H., Krystof G., et al. Urinary catecholamine excretion and thyroid hormone blood level in the course of severe acute brain damage. Eur J Intensive Care Med 1 (1975) 115-123
123. Rosner M.J., Newsome H.H., and Becker D.P. Mechanical brain injury: the sympathoadrenal response. J Neurosurg 61 (1984) 76-86
124. Siesjo B.K., and Siesjo P. Mechanisms of secondary brain injury. Eur J Anaesthesiol 13 (1996) 247-268
125. Kinoshita K., Kraydieh S., Alonso O., et al. Effect of post-traumatic hyperglycemia on contusion volume and neutrophil accumulation after moderate fluid-percussion brain injury in rats. J Neurotrauma 19 (2002) 681-692
126. del Zoppo G.J., Schmid-Schonbein G.W., Mori E., et al. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 22 (1991) 1276-1283
127. Feuerstein G.Z., Liu T., and Barone F.C. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 6 (1994) 341-360
128. Hartl R., Schurer L., Schmid-Schonbein G.W., et al. Experimental antileukocyte interventions in cerebral ischemia. J Cereb Blood Flow Metab 16 (1996) 1108-1119
129. Kozuka M., Smith M.L., and Siesjo B.K. Preischemic hyperglycemia enhances postischemic depression of cerebral metabolic rate. J Cereb Blood Flow Metab 9 (1989) 478-490
130. Katsura K., Kristian T., Smith M.L., et al. Acidosis induced by hypercapnia exaggerates ischemic brain damage. J Cereb Blood Flow Metab 14 (1994) 243-250
131. Kawai N., Tanaka E., Takata T., et al. Influence of additive hyaluronic acid on the lubricating ability in the temporomandibular joint. J Biomed Mater Res A 70 (2004) 149-153
132. Nabeshima T., Katoh A., Ishimaru H., et al. Carbon monoxide-induced delayed amnesia, delayed neuronal death, and change in acetylcholine concentration in mice. J Pharmacol Exp Ther 256 (1991) 378-384
133. Dietrich W.D., Alonso O., and Busto R. Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke 24 (1993) 111-116
134. McCall A.L. The impact of diabetes on the CNS. Diabetes 41 (1992) 557-570
135. Morrison R.S., Magaziner J., Gilbert M., et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci 58 (2003) 76-81
136. Ancelin M.L., de Roquefeuil G., Ledesert B., et al. Exposure to anaesthetic agents, cognitive functioning, and depressive symptomatology in the elderly. Br J Psychiatry 178 (2001) 360-366
137. Rasmussen L.S., Johnson T., Kuipers H.M., et al. Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients 1. Acta Anaesthesiol Scand 47 (2003) 260-266
138. Milbrandt E.B., and Angus D.C. Potential mechanisms and markers of critical illness-associated cognitive dysfunction. Curr Opin Crit Care 11 (2005) 355-359
139. Sommer B.R., Wise L.C., and Kraemer H.C. Is dopamine administration possibly a risk factor for delirium?. Crit Care Med 30 (2002) 1508-1511
140. Fischer J.E., Rosen H.M., Ebeid A.M., et al. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 80 (1976) 77-91
141. Tuor U.I., Kozlowski P., Del Bigio M.R., et al. Diffusion- and T2-weighted increases in magnetic resonance images of immature brain during hypoxia-ischemia: transient reversal posthypoxia 1. Exp Neurol 150 (1998) 321-328
142. den Heijer T., Oudkerk M., Launer L.J., et al. Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology 59 (2002) 746-748
143. Friedman G., Froom P., Sazbon L., et al. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 52 (1999) 244-248
144. Tardiff B.E., Newman M.F., Saunders A.M., et al. Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg 64 (1997) 715-720
145. Ely E.W., Girard T.D., Shintani A.K., et al. Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients. Crit Care Med 35 (2007) 112-117
146. Pomara N., Facelle T.M., Roth A.E., et al. Dose-dependent retrograde facilitation of verbal memory in healthy elderly after acute oral lorazepam administration. Psychopharmacology (Berl) 185 (2006) 487-494
147. Reichenberg A., Yirmiya R., Schuld A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58 (2001) 445-452
148. Patarca-Montero R., Antoni M., Fletcher M.A., et al. Cytokine and other immunologic markers in chronic fatigue syndrome and their relation to neuropsychological factors. Appl Neuropsychol 8 (2001) 51-64
149. Sharshar T., Gray F., Poron F., et al. Multifocal necrotizing leukoencephalopathy in septic shock. Crit Care Med 30 (2002) 2371-2375
150. Finelli P.F., and Uphoff D.F. Magnetic resonance imaging abnormalities with septic encephalopathy. J Neurol Neurosurg Psychiatry 75 (2004) 1189-1191
151. Wijdicks E.F., and Stevens M. The role of hypotension in septic encephalopathy following surgical procedures. Arch Neurol 49 (1992) 653-656
152. Capuron L., Lamarque D., Dantzer R., et al. Attentional and mnemonic deficits associated with infectious disease in humans. Psychol Med 29 (1999) 291-297
153. Sparkman N.L., Buchanan J.B., Heyen J.R., et al. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci 26 (2006) 10709-10716
154. Barichello T., Martins M.R., Reinke A., et al. Cognitive impairment in sepsis survivors from cecal ligation and perforation. Crit Care Med 33 (2005) 221-223 [discussion: 62-3]
155. Rosene K.A., Copass M.K., Kastner L.S., et al. Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med 96 (1982) 865-870
156. Wang Z.J., Liang C.L., Li G.M., et al. Neuroprotective effects of arachidonic acid against oxidative stress on rat hippocampal slices. Chem Biol Interact 163 (2006) 207-217
157. Vajragupta O., Boonyarat C., Murakami Y., et al. A novel neuroprotective agent with antioxidant and nitric oxide synthase inhibitory action. Free Radic Res 40 (2006) 685-695
158. Bal-Price A., and Brown G.C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 21 (2001) 6480-6491
159. Zhan R.Z., Fujiwara N., and Shimoji K. Regionally different elevation of intracellular free calcium in hippocampus of septic rat brain. Shock 6 (1996) 293-297
160. Kadoi Y., Saito S., Kunimoto F., et al. Impairment of the brain beta-adrenergic system during experimental endotoxemia. J Surg Res 61 (1996) 496-502
161. Sharshar T., Hopkinson N.S., Orlikowski D., et al. Science review: the brain in sepsis-culprit and victim. Crit Care 9 (2005) 37-44